Insulet Corp PODD
News
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Diabetes stocks are surprise winners from Novo Nordisk's Wegovy study, analysts say
Insulet shares rebound after results top estimates
Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say
These diabetes stocks, pummeled by the Ozempic craze, now look like bargains, analysts say
Insulet CFO McMillan Steps Down to Join 3M Health Care Business
Insulet shares rise as analysts say weight-loss drug fears may be overblown
Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.
These 20 growth stocks are worth considering on a pullback, says Citi
HP's stock slumps on cautious outlook, VinFast shares on the move again and other stocks in the spotlight
Bunge to replace Signature Bank in S&P 500, stock rallies 7%
Silicon Valley Bank out of S&P 500 index; Insulet selected to replace it
Insulet Up on S&P 500 Inclusion; SVB Financial Out